Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S (NYSE:NVO), is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs, including Ozempic and Wegovy.
諾和諾德公司（NYSE：NVO）總裁兼首席執行官拉斯·弗魯埃爾加德·約爾根森將面臨美國議員關於該公司糖尿病和減肥藥物價格飛漲的嚴厲質詢，包括奧澤匹克和威果維。
The United States Senate Committee on Health, Education, Labor, and Pensions (HELP) hearing is scheduled for Tuesday, September 24th.
美國參議院衛生、教育、勞工和養老金委員會（HELP）聽證會定於9月24日星期二舉行。
Leading the charge is Senator Bernie Sanders, chair of the Senate committee, who has been outspoken about the high cost of these medicines.
參議員伯尼·桑德斯領銜，他是參議院委員會主席，長期以來一直在大聲疾呼這些藥物的高昂成本。
Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
此外還有報道稱：新秋葉公司並不像一個藥物卡特爾，首席執行官爲零售高昂的奧澤匹克辯護。
The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices the pharmaceutical industry charges for prescription drugs in the U.S.
美國總統喬·拜登和參議員伯尼·桑德斯，參議院衛生、教育、勞工和養老金委員會主席，長期以來一直對美國藥品行業爲處方藥收取的高昂價格表示反對。
Bernie Sanders said the first question he would ask Novo Nordisk's CEO at a Senate committee hearing is why the drugmaker charges up to 10 or 15 times more for Ozempic and Wegovy in the U.S. than other countries.
伯尼·桑德斯表示，在參議院委員會聽證會上，他將問諾和諾德公司首席執行官爲何在美國向奧澤匹克和威果維收取的費用是其他國家的10到15倍。
"This is absurd," Sanders said in an interview late Tuesday. "It is clear that Novo Nordisk is ripping off the American people."
桑德斯在週二晚間接受採訪時說："這太荒謬了。" "很明顯，諾和諾德正在敲詐美國人民。"
Novo Nordisk is expected to defend the current prices, pointing to how most patients are covered by insurance and blaming pharmacy benefit managers for inflating drug prices through rebates.
預計諾和諾德將爲目前的價格進行辯護，指出大多數患者都有保險覆蓋，並指責藥房效益管理者通過回扣來抬高藥品價格。
Jørgensen is likely to highlight the extensive development costs of these drugs, which the company says exceeded $10 billion over three decades.
Jørgensen可能會強調這些藥物的巨額開發成本，該公司表示在過去三十年中超過了100億美元。
Novo Nordisk has invested over $30 billion in expanding its manufacturing capacity since early last year.
諾和諾德自去年初以來已投資超過300億美元用於擴大其製造能力。
However, a Bloomberg analysis shows that Ozempic and Wegovy's enormous sales, which are set to surpass $65 billion by the end of this year, undermine the company's justification for the high prices.
然而，彭博分析顯示，奧司匹克和威達維的巨額銷售額預計將在今年年底超過650億美元，這削弱了公司對高價的辯解。
After accounting for inflation, that figure would surpass the $68 billion Novo had invested in all research and development since the mid-1990s when the company began focusing on this class of drugs.
考慮通貨膨脹後，這一數字將超過90年代中期以來諾和諾德在所有研發上投入的680億美元，當時公司開始專注於這類藥物。
According to some analysts, Novo Nordisk's blockbuster diabetes drug Ozempic and several other well-known medications might be included in Medicare's negotiated prescription drug prices.
根據一些分析師的說法，諾和諾德的拳頭產品糖尿病藥奧司匹克和幾種其他知名藥物可能會列入醫保議價處方藥的價格。
Price Action: NVO stock is down 3.10% at $123.56 at the last check Monday.
股價走勢：NVO股票上一次檢查時下跌3.10%，報123.56美元。
- Tesla And Chinese EV Startups Outpace Toyota, Volkswagen In Critical Software Race: Report.
- 特斯拉和中國電動汽車初創企業在關鍵軟件競賽中超越豐田、大衆：報告。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
